Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.

Autor: Micallef IN; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Stiff PJ; Division of Hematology/Oncology, Loyola University, Chicago, Illinois., Nademanee AP; City of Hope Comprehensive Cancer Center, Duarte, California., Maziarz RT; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon., Horwitz ME; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, North Carolina., Stadtmauer EA; Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania., Kaufman JL; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia., McCarty JM; Department of Internal Medicine, Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia., Vargo R; Sanofi, Cambridge, Massachusetts., Cheverton PD; Sanofi, Cambridge, Massachusetts., Struijs M; Sanofi, Naarden, The Netherlands., Bolwell B; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., DiPersio JF; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: jdipersi@wustl.edu.
Jazyk: angličtina
Zdroj: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2018 Jun; Vol. 24 (6), pp. 1187-1195. Date of Electronic Publication: 2018 Feb 02.
DOI: 10.1016/j.bbmt.2018.01.039
Abstrakt: The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 µg/kg plerixafor plus 10 µg/kg G-CSF, or placebo plus 10 µg/kg G-CSF to mobilize and collect CD34 + cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% confidence interval [CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95% CI, 53% to 73%, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus 43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%; 95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.
(Copyright © 2018. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: